Intercure Ltd (INCR) Stock Price, Quote & News

Company Profile

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company has a strategic alliance with Cannasoul R&D Ltd. for the research, development, and commercialization of evidence-based cannabis t...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 972 7 746 05012

Fax: 972 9 768 0244

Website: www.intercure.co

Address:

85 Medinat ha-Yehudim Street, Herzliya, Israel

SuperGreenToday Jun. 1 at 6:23 PM

$INCR Share Price: $1.09 Contract Selected: Jan 15, 2027 $2.5 Calls Buy Zone: $0.11 – $0.14 Target Zone: $0.21 – $0.26 Potential Upside: 72% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SuperGreenToday May. 30 at 4:16 AM

$INCR Share Price: $1.19 Contract Selected: Jan 15, 2027 $2.5 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.16 – $0.19 Potential Upside: 73% ROI Time to Expiration: 230 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

realaxelrod May. 27 at 7:02 PM

$INCR Not bad for now

0 · Reply

captain5500 May. 17 at 11:26 PM

Watch $WCT $INCR

0 · Reply

NVDAMillionaire May. 14 at 3:52 AM

$INCR Brilliant piece that captures INCR's situation perfectly. So if you want to update your understanding of INCR or get to know INCR better, this is essential reading. https://everyticker.com/quote/INCR/analysis/intercure-s-post-war-reconstruction-rebuilding-a-cannabis-leader-while-fighting-for-its-nasdaq-listing-nasdaq-incr

1 · Reply

realaxelrod May. 1 at 7:18 AM

$INCR A pretty good report. The second half of 2025 showed strong growth. Combined with U.S. regulatory changes expected in June and potential compensation from the war damage claim, it looks like the direction through year-end is very positive. https://finance.yahoo.com/markets/stocks/articles/intercure-announces-2025-results-nis-220500877.html

0 · Reply

daddylongstocking Apr. 23 at 11:32 PM

$INCR dollar tomorrow or a pull back day and run up next week??? Either way I’m happy with it and wish I purchased more

0 · Reply

daddylongstocking Apr. 23 at 9:21 PM

$INCR what a great solid day

0 · Reply

futurewilltell Apr. 23 at 7:49 PM

$INCR

1 · Reply

daddylongstocking Apr. 23 at 7:26 PM

$UCAR check out $INCR its been flying under the radar from most people and being doing well

0 · Reply

InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow

2026-03-03T21:56:02.000Z - 3 months ago

InterCure receives noncompliance notification from Nasdaq

Tue, 03 Mar 2026 16:46:00 -0500 - 3 months ago

InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement

2026-02-19T12:11:38.000Z - 3 months ago

InterCure reports preliminary FY25 revenue NIS 265M

Feb 19, 2026, 7:00 AM EST - 3 months ago

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million

2025-11-03T13:40:21.000Z - 7 months ago

InterCure, Cannasoul sign strategic investment, collaboration agreements

Nov 3, 2025, 8:30 AM EST - 7 months ago

InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation

Oct 8, 2025, 9:40 AM EDT - 8 months ago

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow

2025-10-08T13:05:33.000Z - 8 months ago

InterCure reports 1H revenue NIS 130M vs. NIS 126M last year

2025-09-19T12:55:30.000Z - 9 months ago

InterCure announces acquisition of ISHI for 4.92M ordinary shares

Sep 19, 2025, 8:48 AM EDT - 9 months ago

InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands

May 1, 2025, 4:00 PM EDT - 1 year ago

InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025

2025-02-12T23:40:08.000Z - 1 year ago

InterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak

Feb 12, 2025, 6:35 PM EST - 1 year ago

InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

2024-12-20T13:41:01.000Z - 1 year ago

InterCure secures funding to support recovery of Nir Oz facility

Dec 20, 2024, 8:32 AM EST - 1 year ago

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

Sep 14, 2024, 2:32 PM EDT - 1 year ago

Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company

Aug 29, 2024, 6:03 PM EDT - 1 year ago

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

2024-08-28T13:19:15.000Z - 1 year ago

InterCure announces expansion of partnership with Cookies to Germany

Aug 28, 2024, 8:54 AM EDT - 1 year ago

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

May 22, 2024, 6:45 AM EDT - 2 years ago

InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference

May 1, 2024, 8:27 AM EDT - 2 years ago

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

May 1, 2024, 2:00 AM EDT - 2 years ago

InterCure Annual report: Q4 2023

May 1, 2024, 2:00 AM EDT - 2 years ago

InterCure Earnings release: Q4 2023

Apr 1, 2024, 9:09 AM EDT - 2 years ago

InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million

Mar 22, 2024, 11:58 AM EDT - 2 years ago

InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint

Feb 23, 2024, 12:12 PM EST - 2 years ago

PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape

2024-02-13T21:50:35.000Z - 2 years ago

InterCure provides update on Nir Oz facility in Israel

Feb 13, 2024, 4:46 PM EST - 2 years ago

InterCure Provides an Update Regarding Nir Oz Facility

2024-01-31T14:30:47.000Z - 2 years ago

InterCure to acquire Leon Pharm cannabis pharmacy chain

Jan 31, 2024, 9:27 AM EST - 2 years ago

InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain

2023-10-31T20:41:10.000Z - 2 years ago

InterCure wins Cannolam arbitration proceeding

Oct 31, 2023, 4:39 PM EDT - 2 years ago

InterCure Wins Cannolam Arbitration Proceeding

2023-10-17T21:07:27.000Z - 2 years ago

InterCure provides update regarding security situation in Israel

Oct 17, 2023, 5:04 PM EDT - 2 years ago

InterCure Provides an Update Regarding the Security Situation in Israel

Aug 31, 2023, 7:45 PM EDT - 3 years ago

InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY

Aug 31, 2023, 7:00 AM EDT - 3 years ago

InterCure Earnings release: Q2 2023

2023-07-10T21:01:18.000Z - 3 years ago

InterCure board approves voluntary delisting from TSX

Jul 10, 2023, 5:00 PM EDT - 3 years ago

InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE

Jun 9, 2023, 5:18 PM EDT - 3 years ago

InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

May 15, 2023, 5:59 PM EDT - 3 years ago

InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference

May 15, 2023, 5:45 PM EDT - 3 years ago

InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY

May 15, 2023, 7:00 AM EDT - 3 years ago

InterCure Earnings release: Q1 2023

Apr 25, 2023, 7:19 PM EDT - 3 years ago

InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary

Mon, 24 Apr 2023 17:59:00 -0400 - 3 years ago

InterCure Informs That An Application To Approve a Class Action Against 26 Cannabis Companies in Israel, Including InterCure, Was Filed to The Court In Israel

2023-04-20T12:43:43.000Z - 3 years ago

InterCure enters LOI for business partnership with Tyson 2.0

Apr 20, 2023, 8:30 AM EDT - 3 years ago

InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries

2023-04-12T11:33:10.000Z - 3 years ago

InterCure price target lowered to $5 from $10 at TD Cowen

Apr 4, 2023, 4:30 PM EDT - 3 years ago

InterCure Earnings Call Transcript: Q4 2022

Apr 4, 2023, 4:30 PM EDT - 3 years ago

InterCure Annual report: Q4 2022

Apr 4, 2023, 4:30 PM EDT - 3 years ago

InterCure Earnings release: Q4 2022

Apr 3, 2023, 3:27 PM EDT - 3 years ago

InterCure Reschedules 2022 Full Year Results Conference Call

Mar 31, 2023, 8:00 PM EDT - 3 years ago

InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results

Feb 14, 2023, 8:30 AM EST - 3 years ago

InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

Feb 1, 2023, 8:30 AM EST - 3 years ago

InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better)

Dec 19, 2022, 8:30 AM EST - 3 years ago

InterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske"

Dec 8, 2022, 9:30 AM EST - 3 years ago

InterCure to Participate in Cowen 5th Annual Cannabis Conference

Nov 23, 2022, 4:30 PM EST - 3 years ago

Update regarding Better Transaction

Nov 17, 2022, 8:17 AM EST - 3 years ago

Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

Nov 17, 2022, 8:00 AM EST - 3 years ago

Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

OGI

Nov 15, 2022, 11:18 AM EST - 3 years ago

CORRECTION and MULTIMEDIA UPDATE -- InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth

Nov 15, 2022, 9:03 AM EST - 3 years ago

InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth

Nov 15, 2022, 7:00 AM EST - 3 years ago

InterCure Earnings release: Q3 2022

Nov 11, 2022, 8:32 AM EST - 3 years ago

InterCure Announces Record Preliminary Third Quarter Revenue of Over CAD$39 million – 63% Growth YoY

Sep 16, 2022, 4:30 PM EDT - 4 years ago

Intercure Ltd. Announces Voting Results from its Annual and Special Meeting of Shareholders

Aug 15, 2022, 9:15 AM EDT - 4 years ago

InterCure Reports Record Breaking Second Quarter Financial Results

Aug 15, 2022, 1:20 AM EDT - 4 years ago

InterCure Earnings Call Transcript: Q2 2022

Aug 15, 2022, 1:20 AM EDT - 4 years ago

InterCure Earnings release: Q2 2022

Aug 11, 2022, 10:30 AM EDT - 4 years ago

InterCure to Release its Q2 2022 Results and Hold a Conference Call

Jul 21, 2022, 9:00 AM EDT - 4 years ago

InterCure Reports Record Preliminary 2022 Second Quarter Revenue – More Than Double YoY and 9% QoQ Growth

Jun 21, 2022, 8:40 AM EDT - 4 years ago

InterCure and Cookies Launch Flagship Retail Location in Vienna, Austria

Jun 2, 2022, 8:30 AM EDT - 4 years ago

InterCure and Cookies Successfully Launch Flagship Pharmacy in Be'er Sheva, Israel

May 17, 2022, 1:19 AM EDT - 4 years ago

InterCure Earnings Call Transcript: Q1 2022

May 17, 2022, 1:19 AM EDT - 4 years ago

InterCure Earnings release: Q1 2022

May 16, 2022, 5:50 PM EDT - 4 years ago

InterCure Begins 2022 with Record Breaking First Quarter Financial Results

May 16, 2022, 1:30 AM EDT - 4 years ago

InterCure to Release its Q1 2022 Results and Hold a Conference Call

May 9, 2022, 11:20 AM EDT - 4 years ago

InterCure to Participate in Upcoming Investor Conferences in May 2022

May 3, 2022, 11:28 AM EDT - 4 years ago

InterCure to Participate in A.G.P.'s Spring Consumer Cannabis Conference

Apr 6, 2022, 1:31 AM EDT - 4 years ago

InterCure Earnings Call Transcript: Q4 2021

Apr 6, 2022, 1:31 AM EDT - 4 years ago

InterCure Annual report: Q4 2021

Apr 6, 2022, 1:31 AM EDT - 4 years ago

InterCure Earnings release: Q4 2021

Apr 6, 2022, 12:39 AM EDT - 4 years ago

InterCure Reports Record Breaking Q4 and 2021 Results – Exceeded Preliminary Results

SuperGreenToday Jun. 1 at 6:23 PM

0 · Reply

SuperGreenToday May. 30 at 4:16 AM

0 · Reply

realaxelrod May. 27 at 7:02 PM

$INCR Not bad for now

0 · Reply

captain5500 May. 17 at 11:26 PM

Watch $WCT $INCR

0 · Reply

NVDAMillionaire May. 14 at 3:52 AM

1 · Reply

realaxelrod May. 1 at 7:18 AM

0 · Reply

daddylongstocking Apr. 23 at 11:32 PM

$INCR dollar tomorrow or a pull back day and run up next week??? Either way I’m happy with it and wish I purchased more

0 · Reply

daddylongstocking Apr. 23 at 9:21 PM

$INCR what a great solid day

0 · Reply

futurewilltell Apr. 23 at 7:49 PM

$INCR

1 · Reply

daddylongstocking Apr. 23 at 7:26 PM

$UCAR check out $INCR its been flying under the radar from most people and being doing well

0 · Reply

daddylongstocking Apr. 23 at 2:41 PM

$INCR watching close,

0 · Reply

kebrik Apr. 23 at 2:02 PM

Today's movers: $ISPC, $AIXI, $NNBR, $REPL, and $INCR

0 · Reply

focafoca99 Mar. 3 at 10:36 PM

$INCR got a Nasdaq minimum bid notice

0 · Reply

BillionerOfKing Feb. 27 at 12:13 AM

$INCR Current Stock Price: $0.80 Contracts to trade: $2.5 INCR Apr 17 2026 Call Entry: $0.05 Exit: $0.08 ROI: 79% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ProfessorDman1 Feb. 19 at 3:43 PM

$INCR should be over $1 .. great PR this morning … added some sub .90 cents

0 · Reply

ProfessorDman1 Feb. 19 at 3:13 PM

$INCR should break $1 level ✍️🆙

0 · Reply

ProfessorDman1 Feb. 19 at 3:08 PM

$KNRX from .80s to $3 225% $INCR next one to get volume .. sub $1 buying

0 · Reply

ProfessorDman1 Feb. 19 at 2:49 PM

$INCR same chart 📊.. good PR out $KNRX 150% run ? ✍️✍️🆙

0 · Reply

DARKP00L Feb. 19 at 12:19 PM

$INCR 07:07 on Feb. 19 2026 InterCure Posts Preliminary NIS 265M Revenue For 2025, An 11% YoY Rise, With 2H Revenue Nearly 20% Higher Than Prior Year #tradeideas

0 · Reply

Market Cap	56.87M
Revenue (ttm)	78.49M
Net Income (ttm)	-10.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13.21%
Debt to Equity Ratio	0.18

Volume	63,000
Avg Vol	35,180
Day's Range	N/A - N/A
Shares Out	54.68M
Stochastic %K	54%
Beta	1.38
Analysts	Strong Buy
Price Target	$7.00